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Abstract
Gastric reflux may be considered a para-physiological event that may occur up to 50 times 
a day. It usually happens when gas (less commonly liquids) flow back from stomach 
into esophagus. However, when defense mechanisms leave, disease may progress. If the 
esophagus is the trigger, gastroesophageal reflux disease (GERD) emerges. The prevalence 
of GERD in the primary care setting seems to be even more evident when one considers 
that, in the United States, 4.6 million office encounters annually are primarily for GERD, 
whereas 9.1 million encounters include GERD in the top 3 diagnoses for the encounter. 
GERD constitutes also the most frequently first-listed gastrointestinal diagnosis in ambu-
latory care visits. In addition, the extraesophageal manifestations of reflux, including 
LPR, asthma, and chronic cough, have been estimated to cost $5438 per patient in direct 
medical expenses in the first year after presentation and $13,700 for 5 years. Presently, the 
newest alginate compounds renowned the interest in this attracting and stimulating area. 
In this regard, a new medical device (Marial®), unique still now possessing the indica-
tion for both GERD and LPR, has been recently launched in the Italian market, two large 
surveys were conducted in Italy: RELIEF, involving 86 otolaryngologists, and EMERGE, 
involving 56 gastroenterologists. The aims of these surveys were: (1) to define clinical 
characteristics, including previous treatment, of the patients referred to consultation; (2) 
to evaluate the reliability of RFS, GIS, and RSI questionnaires in real-world settings, such 
as specialist office; and (3) to investigate the patients’ perception of efficacy of the pre-
scribed therapy, based on the best practice and considering also the new medical device 
Comparing the patients’ perception of treatment efficacy, reduction in RSI values for each 
single symptom before and after a 4 week-treatment with Marial® alone or with PPI in 
add-on in EMERGE and RELIEF patients are reported. Marial® alone treatment induced 
a statistically significant higher reduction in each single symptom in RELIEF patients than 
in EMERGE patients, with the exception of heartburn, chest pain, indigestion, or stomach 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
acid coming up. Similar results were obtained evaluating the reduction in RSI values in 
patients treated with PPI in add-on that was able to determine a higher statistically sig-
nificant decrease in RELIEF than in EMERGE patients in each single symptom, with the 
exception of heartburn, chest pain, indigestion, or stomach acid coming up.
Keywords: regenerative medicine, GERD, LPR
1. Background
Actually, gastric reflux may be considered a para-physiological event that may occur up to 
50 times a day. It usually happens when gas (less commonly liquids) flow back from stom-
ach into esophagus. However, when defense mechanisms leave, disease may progress. If 
the esophagus is the trigger, gastroesophageal reflux disease (GERD) emerges. On the other 
hand, laryngopharyngeal reflux (LPR) is considered an extraesophageal manifestation of the 
GERD. Both GERD and its extraesophageal manifestation are very common in clinical prac-
tice. Both disorders have a relevant burden for the society: many pharmaco-economic studies 
were conducted in the United States. In population-based studies, 19.8% of North Americans 
complain of GERD symptoms, including heartburn and regurgitation, at least weekly [1]. 
Likewise, in the late 1990s, GERD accounted for $9.3 to $12.1 billion in direct annual health-
care costs in the United States, higher than any other digestive disease. Consequently, acid-
suppressive agents are still the leading pharmaceutical expenditure in the United States.
The prevalence of GERD in the primary care setting seems to be even more evident when one 
considers that, in the United States, 4.6 million office encounters annually are primarily for 
GERD, whereas 9.1 million encounters include GERD in the top 3 diagnoses for the encounter. 
GERD constitutes also the most frequently first-listed gastrointestinal diagnosis in ambula-
tory care visits [2, 3]. In addition, the extraesophageal manifestations of reflux, including LPR, 
asthma, and chronic cough, have been estimated to cost $5438 per patient in direct medical 
expenses in the first year after presentation and $13,700 for 5 years. Estimates of the economic 
burden of extraesophageal reflux have shown that expenditures for extraesophageal manifesta-
tions of reflux could surpass $50 billion, 86% of which could be attributable to pharmaceutical 
costs [2, 3]. In addition, the National Health Care Survey carried out by the Center for Disease 
Control and Prevention has reported that the main complaint for primary care patient visits was 
cough in 6.1%, throat symptoms in 4%, and asthma in 2.8% [4]. Within these visits for cough, 
asthma, and throat symptoms are contained the hidden prevalence of extraesophageal manifes-
tations of GERD, which to date have not been adequately addressed from a medical or surgical 
perspective due to their perceived obscurity. Therefore, the gastric reflux, globally understood, 
represents a very important medical issue that deserves adequate attention in daily practice.
From a pathophysiological point of view, gastric reflux includes different mechanisms, such 
as the provocation and perception of reflux. The transient lower esophageal sphincter relax-
ations (TLESR), hiatus hernia, acid pocket, visceral hypersensitivity, and obesity represent 
important causes of gastric reflux. Impaired esophageal, and extraesophageal, mucosal 
Esophageal Cancer and Beyond48
integrity, poor esophageal clearance, and delayed gastric emptying could be associated with 
GERD development. In addition, another pathogenic factor is a neural reflex sustained by 
acid exposure: the so-called Reflex-Reflux [5].
Distinguishing whether cough, LPR, and asthma may be sustained by GERD remains dif-
ficult challenging for both the primary care physician and the specialist. The distinction 
between them is clinically relevant as treatment of GERD with the intent of improving or 
curing extraesophageal manifestation could be ineffective. To review the current literature on 
extraesophageal manifestations of reflux should assist in clinical decision making.
The Montreal Classification gave the most recent consensus definition of GERD. This document 
defines GERD as heartburn symptoms or complications resulting from the reflux of gastric con-
tents into the esophagus, up to the oral cavity, and lungs [5]. GERD is again classified into two 
subgroups. The first subgroup is represented by GERD with heartburn symptoms but without 
endoscopic evidence of mucosal erosions (the so called Non-Erosive Reflux Disease or NERD). 
The second sub-group is GERD with heartburn symptoms accompanied by objective evidence 
of erosions, ulcers, and inflammation (the so called Erosive Reflux Disease or ERD) [6].
It has to be considered that functional heartburn might fall under endoscopic negative disease. 
However, it is important to note that it is a distinct entity from NERD. NERD is usually defined 
as typical reflux symptoms without evidence of reflux disease in endoscopy but abnormal acid 
exposure on the impedance-pH monitoring and is responsive to proton pump inhibitors - 
PPI [7, 8]. Functional heartburn on the other hand, as defined by Rome IV classification, is a 
retrosternal burning discomfort or pain refractory to anti-secretory therapy without presence 
of GERD, histopathologic abnormality, motility disorder or structural abnormality for at least 
3 months with symptoms onset at least 6 months prior to the diagnosis [5].
As just defined, stomach content may also reflux outside of the esophagus into respiratory 
organs, such as extraesophageal reflux, including LPR. LPR is most commonly manifested as 
laryngeal symptoms such as coughing, hoarseness, dysphagia, globus, and sore throat, but 
there can be signs also of nose, sinus, ear, and eye involvement [9]. Epidemiological stud-
ies have shown that the prevalence of this LPR may be extremely high, that it has certain 
characteristics of an outbreak and that it is one of the most common causes of patient visits to 
their family medicine physicians, but also to otolaryngologists, gastroenterologists, pediatri-
cians, pulmonologists, allergists, and psychiatrists [1, 10–13]. Today it has been proven that 
gastroesophageal reflux is not the only cause of LPR. LPR is a multifactorial syndrome with 
a vast clinical representation, during the disease and with complications, so it requires and 
deserves a multidisciplinary approach. Based on newly discovered findings about the spe-
cific pathogenesis of the disease, LPR may be considered a new clinical entity [11–13]. As 
once pointed out, GERD is caused by the lower esophageal sphincter dysfunction and the 
dysfunction of the stomach emptying mechanism. Esophageal mucosa has protective mecha-
nisms against aggressive factors of the stomach content (mucosal barrier) and it remains intact 
when a physiological reflux occurs, which normally happens at night. However, laryngeal 
and pharyngeal mucosa do not possess the esophageal protective mechanisms, so acid and 
peptic activity of the stomach content quickly leads to mucosal lesions. Notably, laryngopha-
ryngeal reflux occurs most commonly during the day as a result of the upper esophageal 
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sphincter dysfunction. This aspect is intriguing as typical GERD symptoms usually occur 
in supine position and overnight. However, acidity of the stomach content is not the only 
cause of LPR. Pepsin with its proteolytic effects can be the determining factor. Other pos-
sible etiological factors are pancreatic proteolytic enzymes, bile salts, and bacteria [1, 13, 14]. 
Extraesophageal manifestations of stomach content reflux have only recently started being 
seen as important based on the assumption of their important role in causing respiratory tract 
diseases. In clinical practice, LPR is mostly not recognized because it may be a “silent reflux” 
and diagnostic and therapeutic protocols are still inadequate, so proper treatment is usually 
delayed. Laryngeal symptoms are the most common, so patients are managed by otolaryngol-
ogists. Indeed, otolaryngologists have developed the diagnostic Reflux Symptom Index (RSI) 
questionnaire based on the importance of certain disease symptoms and the Reflux Finding 
Score (RFS) based on frequency of pathological changes determined by laryngoscopy [15]. On 
the other hand, considering the high prevalence of the disease and uncharacteristic clinical 
image, most patients report to their family medicine physicians [14–17]. For family medicine 
physicians LPR represents an important medical problem and a challenge in fast diagnostics, 
proper treatment, and proper selection of patients who require additional multidisciplinary 
diagnostic procedures. Knowledge of pathogenic pathway of the disease and its clinical mani-
festations can help physicians in creating an adequate program for prevention, early diagnosis, 
and adequate therapy for LPR. In particular, it has to be considered that untreated LPR can be 
one of the etiological causes of laryngeal cancer. The development of the disease can be benign 
or malignant and life threatening, and all of its forms can considerably affect life quality in 
patients. Laryngeal pathological changes could be discovered with laryngoscopy, and some 
even with detailed esophagogastroscopy. These changes may include: edema, hyperemia, or 
erythema of the vocal chords and laryngeal edges, ventricular obliteration, granulation, pres-
ence of dense endolaryngeal secretion, and hypertrophy of the posterior commissure [10, 15]. 
As consequence, an appropriate diagnosis of LPR represents a challenge for general practitio-
ner and specialists. A large number of clinical studies confirmed low specificity and sensitiv-
ity of diagnostic tests such as laryngoscopy, esophagogastroscopy, proximal pH monitoring 
(hypopharyngeal and oropharyngeal). Evaluation of symptoms using the Reflux Symptom 
Index is considered to be the basic diagnostic procedure. A newer method of measuring sali-
vary pepsin (Pep-test) can confirm LPR diagnosis because its sensitivity and specificity is 87% 
[13]. In this regard, it has to be noted that pepsinogen is produced only in the stomach, so 
pepsin may be envisaged as a specific biomarker for gastric reflux. The Pep-test is a fast and 
non-invasive method and could have a wide variety of uses in primary health care.
LPR therapy is complex and requires also modification of the patient’s lifestyle and habits. 
Body weight reduction and physical activity, quitting cigarettes and alcohol use are one of 
the first steps in lowering the intensity of symptoms in patients [17]. Nutritional interven-
tions with correct food choices and bowel movement regulation lead to lowering dyspeptic 
complains, but also lower the number of reflux episodes. Emptying of the bowels causes 
lower intra-abdominal pressure, which leads to lower possibility of stomach content reflux 
into the esophagus, larynx and pharynx. Obesity, or more precisely high BMI, so includ-
ing overweight, is an independent factor in stomach reflux occurrence because of its specific 
effect mechanism on the gastroesophageal juncture [17]. LPR treatment and management is 
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supposed to reduce the acidity or stomach contents and neutralize acid-peptic activity in 
larynx, pharynx and esophagus. High dosages of PPI (proton pump inhibitors) have shown 
the best effects in reducing reflux in the course of 24 h. Alkaline water and alginates show a 
positive additional effect in lowering acid-peptic activity in the larynx and pharynx. Patients 
are supposed to have long-term treatment during the course of 6 months because of high sen-
sitivity of the mucosal membrane in the stomach and pharynx. Difficult cases with a proven 
hiatal hernia can be considered for surgical treatment as well [6].
Therefore, acid suppression is the mainstay of therapy for gastric reflux, and PPIs are the 
most effective drug in this approach [18, 19]. Although PPIs are the treatment of choice for 
GERD, still approximately one-third of patients with GERD fail to respond symptomatically to 
a standard dose PPI, either partially or completely [20]. Actually, NERD accounts for 60–70% 
of GERD patients and is considered the most common presentation of GERD. However, only 
approximately 30–40% of NERD patients respond to a standard dose of PPIs, much lower than 
that in erosive esophagitis, and the low response rate to PPIs in NERD patients is the main con-
tributor to the high portion of PPI failure phenomenon in GERD, and also LPR, management 
[21]. The mechanisms of failure of PPI therapy are complex and multifactorial [20, 22–24]. 
Consequently, other medications should be considered and used. In this context, alginates and 
histamine type-2 receptor antagonists (H2RAs) may provide additional benefit for symptom 
relief in patients with persistent symptoms despite PPI therapy and can be considered as add-
on therapy for patients who fail with a PPI. However, because of the concern about tolerance, 
H2RA is suggested to be taken on demand or intermittently. PPI-refractory GERD (and LPR), 
defined as persistent reflux symptoms not responding to a double dose of a PPI therapy dur-
ing a treatment period of at least 12 weeks, is an important issue in clinical practice and poses 
a great challenge for general practitioners, internists, gastroenterologists, and otolaryngolo-
gists [20]. Compliance with therapy should be verified first by the physician, and the presence 
of functional gastrointestinal disorders, psychological distress, functional heartburn or other 
esophagitis not related to reflux should also be carefully evaluated in these patients.
On the basis of these concepts, alginate may be considered a fruitful and relevant option 
in many patients with reflux disease. In particular, the knowledge about the utility of algi-
nates derives from an interesting research area investigating the pathogenic role of the 
so-called “acid pocket.” The acid pocket is a short zone of unbuffered highly acidic gastric 
juice that accumulates in the proximal stomach after meals. Serving as the source of acid 
reflux, the acid pocket increases the propensity for acid reflux by all conventional mecha-
nisms, such as TLESR and hiatus hernia, and has been considered as an important cause 
of GERD [25, 26]. Alginate is an anionic polysaccharide occurring naturally in brown algae 
and has a unique property in the treatment of gastric reflux by eliminating the acid pocket. 
Alginate-antacid formulation can reduce postprandial symptoms by neutralizing the acidity 
of gastric contents. In addition to neutralizing the gastric acidity, more importantly, alginate 
and bicarbonate, usually contained in an alginate-based formulation, form a foamy gel that 
is like a raft floating on the surface of gastric contents after interacting with gastric acid, 
and this barrier-like gel displaces the acid pocket from the esophageal-gastric junction and 
protects both the esophageal and the upper respiratory mucosa from the acid and non-acid 
reflux by gel coating [27–30]. Like an antacid, an alginate-based formulation demonstrates 
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an immediate onset of effect within 1 h of administration, which is faster than a PPI and 
H2RA [31]. Compared with antacids, an alginate-based formulation is more effective than 
an antacid in controlling postprandial esophageal acid exposure and quickly relieving reflux 
symptoms, including heartburn, regurgitation, vomiting and belching, with longer dura-
tion [32–34]. Alginate-based formulations are also non-inferior to omeprazole in achieving a 
heartburn-free period in moderate episodic heartburn [35]. Therefore, alginate has the special 
properties of protection of the esophageal and upper respiratory mucosa from acid and non-
acid reflux and displacement of acid pocket away from the esophagus, all of which make 
alginate an attractive agent in the management of refractory reflux symptoms with a cause 
other than by acid, such as NERD [36]. Compared with placebo, an alginate-antacid formula-
tion demonstrated superior relief of reflux symptoms including heartburn and regurgitation 
in both patients with NERD and erosive esophagitis in a double-blind randomized controlled 
trial [37]. In another double-blind randomized clinical trial comparing the efficacy of alginate 
to omeprazole in patients with NERD, alginate demonstrated non-inferiority to omeprazole 
and was as effective as omeprazole for symptomatic relief [38]. Furthermore, adding alginate 
to a PPI can significantly relieve heartburn compared to using a PPI alone in patients with 
NERD, suggesting an additional benefit of alginate as add-on therapy in the management of 
refractory symptoms [39].
Interestingly, in a meta-analysis study, six of nine randomized trials found no difference 
between the PPI and placebo groups for LPR, whereas three trials exhibited statistically sig-
nificant results [1]. In a systemic review, three of four randomized controlled studies revealed 
that prokinetic agents significantly reduced LPR symptoms, but there were too many study 
limitations to draw firm conclusions [40]. In a small randomized controlled study, a liquid 
alginate suspension could achieve significant improvement in the symptom scores and clini-
cal findings of LPR [41].
Therefore, on the basis of this discussed background, the management of suspected LPR is 
intriguing as it is very difficult, if even possible, to make a definitive diagnosis with the tools 
currently available [42]. If there is no doubt that many patients do have LPR symptoms, the 
probability of suspecting LPR, especially when typical reflux symptoms are lacking and PPIs 
do not improve symptoms, are low, mainly in non-specialist setting. LPR management is 
responsible of high economic burden mainly related to the prescription of PPIs, which may 
be, in most cases, not justified [3, 43, 44]. Therefore, in patients, initially visited by GP, who 
do not respond to a 2 to 3-month course of double dose PPI therapy, the role of the oto-
laryngologist is to document the presence of signs and symptoms suggestive of LPR with 
appropriate (i.e., validated and reproducible) investigations, namely fiber-endoscopy, and 
validated questionnaire (for example RSI and RFS). If LPR is documented, it is reasonable 
empirically testing these patients on PPIs to check for reflux control may be useful to select 
PPI-responder patients. If PPI are not adequate to control symptoms an add-on treatment 
should be prescribed. On the basis of the above-mentioned concepts, alginate could be a first-
choice option. As a matter of the fact, as there is no specific and focused medication able to 
irreversibly inactivate pepsin and block acid production, other compounds have place in LPR 
management, including medical devices with barrier effect. In the current scenario, an effec-
tive supportive strategy may be constituted by compounds able to strengthen the epithelial 
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barrier providing protection from acid and pepsin and promoting mucosal healing. In other 
words, an old concept could be revised for LPR therapy: the “cytoprotection” of mucosal 
tissues [45]. Mucosal cytoprotection was an ideal target of two main drug classes: prostaglan-
dins and sucralfate. Many clinical trials supported this theory that met favorable impression 
some decades ago [46–49].
Presently, the newest alginate compounds renowned the interest in this attracting and 
stimulating area. In this regard, a new medical device (Marial®), unique still now pos-
sessing the indication for both GERD and LPR, has been recently launched in the Italian 
market. It is an innovative gel compound, containing magnesium alginate and E-Gastryal® 
(hyaluronic acid, hydrolyzed keratin, Tara gum, and Xantana gum). E-Gastryal® is a com-
plex of phyto-polymers, Tara and Xantana gums, that are natural polysaccharides with high 
molecular weight and partially hydrosoluble, and able to provide viscosity to the solution 
and to generate a support frame where keratin peptide chains and hyaluronic acid anchor. 
Hyaluronic acid (HA) is a biopolymer with medium molecular weight characterized by 
optimal hygroscopic and hydrodynamic features. The chemical–physical properties of the 
polymeric complex confer mucoadhesiveness to E-Gastryal® so increasing the contact sur-
face and the residence time on the mucous membranes of larynx, pharynx, and esophagus. 
In this context, hyaluronic acid is extremely bioavailable and able to carries out its activity 
aimed to induce repairing and regenerating the damaged epithelium. HA, by its hydro-
philic essence, realizes a favorable milieu for cellular migration; in addition, HA, having 
a scavenger activity of free radicals, exerts a protective role towards oxide damage and 
proteolytic enzymes, such as pepsin.
Hydrolyzed keratin, an indigestible substance, increases the solidity and the resistance of 
E-Gastryal®, enhancing the barrier effect. Really, keratin abounds with cysteine, amino acid 
sulfide, that forms disulfide bridges extremely firm and able to link the amino acid chains, 
making an helical structure characterized by difficult dissolution and resistant to attack of 
acid and pepsin. The alginate has the peculiar property of a boating raft at the acid pocket and 
selectively inhibits pepsin by mannuronic acid, highly contained in the specific alginate [50]. 
In particular, this medical device contains magnesium alginate with high ratio mannuronic 
acid/glucuronic acid and with raised viscosity shaping a stable and compact raft.
For these reasons, two large surveys were conducted in Italy, involving both otolaryngolo-
gists and gastroenterologists. The aims were to define the patients’ characteristics, including 
the clinical features, the assessment of treatments, and new therapeutic approaches in view of 
the new medical device Marial®.
2. Clinical experience
As pointed out, the gastroesophageal reflux is considered a normal physiological process 
that usually happens after eating in healthy infants, children, young people and adults. In 
contrast, gastroesophageal reflux disease occurs when the effect of GER leads to symptoms 
severe enough to merit medical treatment. In clinical practice, it is difficult to differentiate 
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None of 
the time
1
A little of 
the time
2
Some of 
the time
3
All of the 
time
4
In the past week
1. How often have you had the following symptoms
a. Pain in chest/behind the breastbone?
b. Burning sensation in your chest or behind the breastbone?
c. Regurgitation or acid taste in your mouth?
d. Pain or burning in upper stomach?
e. Sore throat or hoarseness that is related to your heartburn or acid 
reflux?
2. How often have you had difficulty in getting a good night’s sleep 
because of your symptoms?
3. How often have your symptoms prevented you from eating or 
drinking any of the foods you like?
4. How often have your symptoms kept you from being fully 
productive in your job or daily activities?
5. How often do you take additional medication other than what the 
physician told you to take (such as Gaviscon, Maalox)?
Table 1. GERD Impact Scale (GIS).
between GER and GERD, and the terms are used interchangeably by health professionals and 
families alike. There is no simple, reliable and accurate diagnostic test to confirm whether 
the condition is GER or GERD, and this in turn affects research and clinical decisions [50–52]. 
Furthermore, the term GERD covers a number of specific conditions that have different effects 
and present in different ways. This makes it difficult to identify the person who genuinely 
has GERD, and to estimate the real prevalence and burden of the problem. Nevertheless, 
regardless of the definition used, GERD affects many subjects, who commonly seek advice 
from primary, secondary or tertiary care. As a result, it constitutes a major health burden 
for the Health Service. Moreover, if gastric refluxate moves more proximally into the laryn-
gopharynx, it is defined laryngopharyngeal reflux (LPR). LPR should be considered as part 
of extraesophageal reflux (EER), reflux involving structures other than, or in addition to, the 
esophagus, and airway reflux involving proximal gastric reflux into the airways. LPR contrib-
utes to several otorhinolaryngologic symptoms and inflammatory disorders, and probably 
also to neoplastic diseases of the laryngopharynx, and seems to be also as common in children 
and infants as adults.
From a diagnostic point of view, GERD and LPR diagnosis may be performed on a clinical 
ground as there is no gold-standard diagnostic tool. In this regard, some questionnaires may 
very fruitful in clinical practice: Reflux Finding Score (RFS) based on signs viewed by laryn-
goscopy, Reflux Score Index (RSI) based on reflux symptoms, and GERD Impact Scale (GIS) 
based on frequency of symptoms, as reported in the tables (Tables 1–3).
Esophageal Cancer and Beyond54
From a management point of view, the guidelines suggest to give advice about GER and reas-
sure patients and caregivers. Patients with dyspepsia with mild–moderate symptoms and 
without severe complications, such as bleeding, painful complaints, vomiting, could be treated 
with empirical full-dose PPI therapy for 4 weeks. Patients with GERD could be treated with a 
full-dose PPI for 4 or 8 weeks. If symptoms recur after initial treatment, a PPI could be offered 
at the lowest dose possible to control symptoms. In addition, it is recommended to encour-
age people who need long-term management of dyspepsia symptoms to reduce their use of 
prescribed medication stepwise: by using the effective lowest dose, by trying ‘as-needed’ use 
when appropriate, and by returning to self-treatment with antacid and/or alginate therapy 
(unless there is an underlying condition or co-medication that needs continuing treatment). It 
is also necessary to advise people that it may be appropriate for them to return to self-treat-
ment with antacid and/or alginate therapy (either prescribed or purchased over-the-counter 
and taken as needed). Finally, it is important to avoid long-term, frequent dose and continu-
ous antacid therapy (it only relieves symptoms in the short term rather than preventing them).
On the basis of these considerations, proposed by guidelines, alginates may be considered as 
a valid and reasonable therapeutic option. A new medical device (Marial®), unique still now 
possessing the indication for both GERD and LPR, has been recently launched in the Italian 
market [53]. It is an innovative gel compound, containing magnesium alginate and E-Gastryal®. 
E-Gastryal® is a complex of phyto-polymers, keratin, Tara and Xantana gums, that are natural 
polysaccharides with high molecular weight and partially hydrosoluble, and able to provide 
viscosity to the solution and to generate a support frame where keratin peptide chains and hyal-
uronic acid anchor. Hyaluronic acid (HA) is a biopolymer with medium molecular weight char-
acterized by optimal hygroscopic and hydrodynamic features. The chemical–physical properties 
of the polymeric complex confer mucoadhesiveness to E-Gastryal® so increasing the contact 
surface and the residence time on the mucous membranes of larynx, pharynx, and esophagus.
Within the last month, how did the following problems affect you? 0 = no problem
5 = severe problem
1. Hoarseness or a problem with your voice 0 1 2 3 4 5
2. Clearing your throat 0 1 2 3 4 5
3. Excess throat mucus or postnasal drip 0 1 2 3 4 5
4. Difficulty swallowing food, liquids, or pills 0 1 2 3 4 5
5. Coughing after you ate or after lying down 0 1 2 3 4 5
6. Breathing difficulties or choking episodes 0 1 2 3 4 5
7. Troublesome or annoying cough 0 1 2 3 4 5
8. Sensation of something sticking in your throat or a lump in your throat 0 1 2 3 4 5
9. Heartburn, chest pain, indigestion, or stomach acid coming up 0 1 2 3 4 5
RSI > 13 = Abnormal Total
Abbreviation: RSI, reflux symptom index.
Table 2. Reflux Symptom Index.
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Therefore, two large surveys were conducted in Italy: RELIEF, involving 86 otolaryngologists, 
and EMERGE, involving 56 gastroenterologists [54–56]. The aims of these surveys were: (1) 
to define clinical characteristics, including previous treatment, of the patients referred to con-
sultation; (2) to evaluate the reliability of RFS, GIS, and RSI questionnaires in real-world set-
tings, such as specialist office; and (3) to investigate the patients’ perception of efficacy of the 
prescribed therapy, based on the best practice and considering also the new medical device.
The outcomes of these surveys are here presented and discussed. Now, we would draw the 
conclusive remarks from a pragmatic point of view. So, we compared the most relevant out-
comes obtained by the two surveys.
First, we compared RSI questionnaires: at baseline, RSI questionnaire was filled by 1934 RELIEF 
patients and by 789 EMERGE patients. Globally, 594 (75.3%) EMERGE patients and 1250 
Subglottic edema 0 = absent
2 = present
Ventricular edema 2 = partial
4 = complete
Erythema/hyperemia 2 = arytenoids only
4 = diffuse
Vocal-fold edema 1 = mild
2 = moderate
3 = severe
4 = polypoid
Diffuse laryngeal edema 1 = mild
2 = moderate
3 = severe
4 = obstructing
Posterior commissure hypertrophy 1 = mild
2 = moderate
3 = severe
4 = obstructing
Granuloma/granulation tissue 0 = absent
2 = present
Thicken laryngeal mucus 0 = absent
2 = present
RFS, Reflux Finding Score. RFS > 7 suspect of laryngopharyngeal reflux (LPR).
Table 3. Reflux Finding Score.
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(64.6%) RELIEF patients had positive RSI score. RSI values for each single symptom are analyti-
cally reported in Figure 1. The symptoms with the highest score were: heartburning, sensation 
of something sticking in the throat or a lump in the throat, and clearing throat, whereas breath-
ing difficulties or choking episodes had the lowest score. The total score was 16 [14–20] in the 
EMERGE patients was significantly higher than in the RELIEFE patients: 16 [12–20] (p < 0.001; 
data not shown). Interestingly, RELIEF patients had significantly higher scores for some symp-
toms, including lump sensation, cough, dyspnea, hoarseness, and throat clearing, whereas 
EMERGE patients had higher scores for heartburn and difficult swallowing. So, the clinical 
features were really different in the two populations, such as GERD and LPR patients.
Considering the previous treatments, the frequency of past/current treatments in the EMERGE 
group (Figure 2A) was significantly higher than in RELIEF group (Figure 2B) patients (p < 0.0001): 
this outcome underlines the more intense recourse to medical therapy in GERD patients than in 
LPR patients. Analyzing the treatment options, Figure 3 shows the distribution of different types 
of treatments prescribed in the past (panel A, C) or currently used (panel B, D): monotherapy with 
PPI, PPI in add-on, and Miscellany in EMERGE (panel A, B) and RELIEF (panel C, D) patients. 
LPR patients were more frequently treated with PPI as monotherapy and with miscellany treat-
ments, whereas GERD patients use more commonly PPI plus add-on, even though PPI alone 
are the first-choice therapy also in GERD. Considering the distribution of the new prescribed 
Figure 1. Reflux Symptom Index (RSI) as median values for each single symptom in the EMERGE (no. 789) and in the 
RELIEF population (no. 1934). Scores are reported as medians (bars) with lower and upper quartiles (boxes).
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treatments (i.e., prescriptions made during the visits) and specifically of Marial® as monother-
apy, PPI as monotherapy or PPI in add-on, there was difference in EMERGE (Figure 4A) and in 
RELIEF (Figure 4B) patients (p < 0.0001): LPR patients were preferentially treated with Marial® 
alone, whereas GERD patients were treated essentially with PPI plus add-on.
Figure 2. Distribution of the EMERGE (panel A) or RELIEF (panel B) patients according to the treatments: past, current, 
or never.
Figure 3. Distribution of different types of treatments prescribed in the past (panel A, C) or currently used (panel B, 
D): monotherapy with PPI, PPI in add-on, and miscellany in EMERGE (panel A, B) and RELIEF (panel C, D) patients.
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Figure 4. Distribution of the Marial® as monotherapy, PPI as monotherapy or PPI in add-on in new prescribed treatments 
(i.e., prescription during the visit) in EMERGE (panel A) and RELIEF (panel B) patients.
Figure 5. Reduction in RSI values for each single symptom before and after a 4 week-treatment with Marial® as 
monotherapy in EMERGE and in RELIEF patients.
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Comparing the patients’ perception of treatment efficacy, reduction in RSI values for each 
single symptom before and after a 4 week-treatment with Marial® alone or with PPI in add-
on in EMERGE and RELIEF patients are reported in Figures 5 and 6. Marial® alone treatment 
induced a statistically significant higher reduction in each single symptom in RELIEF patients 
than in EMERGE patients, with the exception of heartburn, chest pain, indigestion, or stom-
ach acid coming up (Figure 5). Similar results were obtained evaluating the reduction in RSI 
values in patients treated with PPI in add-on that was able to determine a higher statistically 
significant decrease in RELIEF than in EMERGE patients in each single symptom, with the 
exception of heartburn, chest pain, indigestion, or stomach acid coming up (Figure 6).
In conclusion, these two surveys provided some interesting outcomes: (i) diagnostic ques-
tionnaires (RSI, RFS, and GIS) are reliable and useful both during the visit and to orient 
the treatment decision; (ii) GERD and LPR present different clinical features; (iii) as con-
sequence the treatments (both previous and actual) are different; (iv) the introduction of 
Marial® significantly affected the otolaryngologist approach and partially the gastroenter-
ologist orientation; (v) Marial® was effective both in LPR and GERD patients; (vi) Marial® 
showed more effectiveness than conventional therapy (PPI plus add-on); and (vii) LPR 
patients were more responsive to medical treatments than GERD patients. Therefore, these 
outcomes may give a pragmatic usefulness to both otolaryngologists and gastroenterolo-
gists in clinical practice.
Figure 6. Reduction in RSI values for each single symptom before and after a 4 week-treatment with PPI + add-on in 
EMERGE and in RELIEF patients.
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